Evidence map›Paper›PMID 40749334›Full record

ReviewPharmacological reviews2025

Advances and challenges in experimental models of posttraumatic epilepsy for therapeutic interventions.

Doodipala Samba Reddy, Victoria M Golub, Sreevidya Ramakrishnan, Severn B Churn, Lee A Shapiro, Jaclyn Iannucci, Asla Pitkänen, Aristea S Galanopoulou, Rama Maganti, Detlev Boison

Erratum issuedAbstract readReview
In one paragraph

Review in Pharmacological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Doodipala Samba ReddyDepartment of Neuroscience and Experimental Therapeutics, Texas A&M University College of Medicine, Bryan, Texas. Electronic address: sambareddy@tamu.edu.
Victoria M GolubDepartment of Neuroscience and Experimental Therapeutics, Texas A&M University College of Medicine, Bryan, Texas.
Sreevidya RamakrishnanDepartment of Neuroscience and Experimental Therapeutics, Texas A&M University College of Medicine, Bryan, Texas.
Severn B ChurnNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Rockville, Maryland.
Lee A ShapiroDepartment of Neuroscience and Experimental Therapeutics, Texas A&M University College of Medicine, Bryan, Texas.
Jaclyn IannucciDepartment of Neuroscience and Experimental Therapeutics, Texas A&M University College of Medicine, Bryan, Texas.
Asla PitkänenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Aristea S GalanopoulouSaul R. Korey Department of Neurology, Isabelle Rapin Division of Child Neurology, Dominick P. Purpura Department of Neuroscience, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York.
Rama MagantiDepartment of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Detlev BoisonDepartment of Neurosurgery, Robert Wood Johnson & New Jersey Medical Schools, Rutgers University, Piscataway, New Jersey; Brain Health Institute, Rutgers University, Piscataway, New Jersey; Rutgers Cancer Institute, Rutgers University, New Brunswick, New Jersey.

Funding

The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy (EpiBioS4Rx) Public Engagement CoreU54NS100064 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ENGEL, JEROME NONE, GALANOPOULOU, ARISTEA S · 2017 to 2021
$21.7M
Translational Platform for Epilepsy Therapy and Biomarker DiscoveryR01NS127524 · NINDS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Denes V. Agoston, LISA D COLES · 2022 to 2026
$11.0M
SUPPORT FOR THE ROSE F KENNEDY IDDRC P50P50HD105352 · NICHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SOPHIE MOLHOLM, Steven Upshaw Walkley · 2021 to 2026
$7.0M
The Role of Adenosine in Ketogenic Diet TherapyR01NS065957 · NINDS · TRINITY COLLEGE · PI BOISON, DETLEV, GEIGER, JONATHAN DAVID · 2010 to 2021
$3.9M
Novel pediatric anticonvulsants for nerve agentsU01NS117209 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2020 to 2024
$3.7M
Neurosteroid Treatment for OP IntoxicationU01NS083460 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2013 to 2017
$3.4M
Therapies for Epilepsy Prevention - Focus on AdenosineR01NS127846 · NINDS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Detlev Boison · 2022 to 2026
$2.1M
Progesterone Receptors and Seizure SusceptibilityR01NS051398 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2007 to 2011
$1.5M
Novel Water-Soluble Adjunct Anticonvulsants for Nerve AgentsU01NS117278 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2020 to 2022
$1.3M
A Neurosteroid-based Novel Treatment for OP-IntoxicationR21NS076426 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2011 to 2012
$806k
Epigenetic Attenuation of Long-Term Effects of Nerve AgentsR21NS099009 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2017 to 2018
$408k
Tonic Inhibition Therapy for Refractory Status EpilepticusR21NS071597 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REDDY, DOODIPALA SAMBA · 2010 to 2011
$399k
NICHD NIH HHS P50 HD105352NINDS NIH HHS R01 NS051398NINDS NIH HHS R01 NS065957NINDS NIH HHS R01 NS127524NINDS NIH HHS R01 NS127846NINDS NIH HHS R21 NS071597NINDS NIH HHS R21 NS076426NINDS NIH HHS R21 NS099009NINDS NIH HHS U01 NS083460NINDS NIH HHS U01 NS117209NINDS NIH HHS U01 NS117278NINDS NIH HHS U54 NS100064
6 · The paper itself

Abstract

Epilepsy affects over 80 million people worldwide, with approximately 40% experiencing refractory seizures. Despite some progress in deciphering the complex process of epileptogenesis, which transforms a healthy brain into one susceptible to epilepsy, there are still no therapies available to prevent this condition. Traumatic brain injury (TBI) is a leading cause of epilepsy in both military and civilian populations, often leading to the complex condition of posttraumatic epilepsy (PTE). Defined as recurrent seizures following TBI, PTE lacks effective treatment options, highlighting the need for improved experimental models and translational interventions. Unveiling disease-modifying therapeutics for epilepsy is a top priority in the field of neurology research. One major obstacle in PTE research is the lack of robust models that accurately reflect the multifaceted and heterogeneous nature of human PTE. Hence, developing disease-modifying treatments requires innovative models that facilitate the identification of novel therapeutic approaches. Establishing clinically relevant animal models is critical for elucidating the pathophysiological mechanisms of epileptogenesis and identifying effective therapies for PTE management. This article describes the opportunities and challenges associated with advances in PTE experimental models, including the call for common data elements to be developed for PTE. Inspired by insights from a 2023 workshop supported by the American Epilepsy Society, this review explores progress in animal models, experimental protocols, biomarkers, and principles of therapeutic interventions for TBI-induced seizures and posttraumatic epileptogenesis. It evaluates the PTE research landscape and critically discusses current strategies, innovations, hurdles and future directions for establishing models that ultimately lead to the development of disease-modifying agents and targeted therapeutic approaches for PTE prevention. SIGNIFICANCE STATEMENT: Posttraumatic epilepsy (PTE) lacks specific therapies due to limited experimental models. Here, we outline the proceedings of the 2023 American Epilepsy Society-supported National Workshop on PTE, covering small and large animal models for PTE research. This article provides insights into recent advancements in experimental paradigms and analyzes the validity and application of these models in identifying interventions to prevent epileptogenesis following traumatic brain injury. We address challenges and obstacles in discovering PTE therapies, offering clinical data context and common themes.

Indexed as

Disease Models, AnimalEpilepsy, Post-TraumaticAnimalsAnticonvulsantsBrain Injuries, TraumaticHumansAnticonvulsants

Identifiers

PMID40749334
PMCPMC12799440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.